AstraZeneca and Dako Denmark A/S announced today that they have entered into a collaboration agreement to develop companion diagnostic tests for multiple AstraZeneca oncology projects, including biologics and small molecules, in various stages of discovery and development.
Under the agreement, the companies will work together to develop diagnostic tests to help physicians determine the most appropriate cancer treatment for patients. The financial terms of the deal were not disclosed.
The collaboration will leverage Dako’s position as a leader in cancer diagnostics and a strong partner in the development of diagnostic tests used in conjunction with drug therapies. AstraZeneca will bring its extensive experience in the development and commercialization of vital oncology products worldwide.
Popularity: 1% [?]
